These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 15901207)
1. Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Granberry MC; Fonseca VA Am J Cardiovasc Drugs; 2005; 5(3):201-9. PubMed ID: 15901207 [TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
3. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Krentz AJ; Bailey CJ Drugs; 2005; 65(3):385-411. PubMed ID: 15669880 [TBL] [Abstract][Full Text] [Related]
5. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Stolar MW; Chilton RJ Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864 [TBL] [Abstract][Full Text] [Related]
6. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality. Pfützner A; Forst T Expert Opin Pharmacother; 2006 Mar; 7(4):463-76. PubMed ID: 16503818 [TBL] [Abstract][Full Text] [Related]
7. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856 [TBL] [Abstract][Full Text] [Related]
8. Pioglitazone: a review of its use in type 2 diabetes mellitus. Waugh J; Keating GM; Plosker GL; Easthope S; Robinson DM Drugs; 2006; 66(1):85-109. PubMed ID: 16398569 [TBL] [Abstract][Full Text] [Related]
9. [Therapy of type 2 diabetes. Critical evaluation of oral antidiabetic drugs]. Landgraf R MMW Fortschr Med; 2000 May; 142(21):33-7. PubMed ID: 10872292 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular manifestations of insulin resistance. Chahwala V; Arora R Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874 [TBL] [Abstract][Full Text] [Related]
11. Analysis of Hypoglycemic Drugs by Liquid Chromatography-Tandem Mass Spectrometry. Jannetto PJ; Langman LJ Methods Mol Biol; 2024; 2737():297-306. PubMed ID: 38036831 [TBL] [Abstract][Full Text] [Related]
12. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Fonseca VA Am J Cardiol; 2003 Aug; 92(4A):50J-60J. PubMed ID: 12957327 [TBL] [Abstract][Full Text] [Related]
13. Oral pharmacologic management of type 2 diabetes. Riddle MC Am Fam Physician; 1999 Dec; 60(9):2613-20. PubMed ID: 10605995 [TBL] [Abstract][Full Text] [Related]
14. Divergent effects of various diabetes drugs on cardiovascular prognosis. Bell DS; Patil HR; O'Keefe JH Rev Cardiovasc Med; 2013; 14(2-4):e107-22. PubMed ID: 24448252 [TBL] [Abstract][Full Text] [Related]
15. Type 2 diabetes: glycemic targets and oral therapies for older patients. Lardinois CK Geriatrics; 1998 Nov; 53(11):22-3, 27-8, 33-4 passim. PubMed ID: 9824974 [TBL] [Abstract][Full Text] [Related]
16. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Plosker GL; Faulds D Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691 [TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment of type 2 diabetes mellitus. Israili ZH Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322 [TBL] [Abstract][Full Text] [Related]
19. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Lebovitz HE Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077 [TBL] [Abstract][Full Text] [Related]
20. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Ou HT; Chang KC; Li CY; Wu JS Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]